News

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced ...
pharmaphorum3d
Veru shares plunge despite positive data in obesity trial
Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...
Morningstar13d
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant and a clinically ...
Nasdaq29d
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
About Veru Inc.Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy®). The trial met its prespecified primary endpoint with a statistically significant ...
The Globe and Mail29d
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Detailed price information for Veru Inc (VERU-Q) from The Globe and Mail including charting and trades.
TMCnet29d
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
About Veru Inc. Veru is a late clinical stage biopharmaceutical ... patients receiving semaglutide (Wegovy ®). The trial met its prespecified primary endpoint with a statistically significant and a ...